DIUXF (Diaceutics) Growth Rank: 10 (As of Jul. 17, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIUXF Diaceutics PLC DIUXF
80 GF Score
Price $2.00
GF Value $2.05
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Diaceutics Growth Rank?

Diaceutics DIUXF 80 Growth Rank is 10 as of Jul. 17, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review.

Diaceutics has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

DIUXF vs VEEV, BTSG, TEM: Growth Rank Comparison

For the Health Information Services subindustry, Diaceutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diaceutics Growth Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Diaceutics's Growth Rank falls into.


DIUXF
80GF Score
Diaceutics PLC DIUXF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Diaceutics (DIUXF) has a Growth Rank of 10 as of Jul. 17, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Diaceutics and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Diaceutics' Growth Rank has ranged from 2.00 to 10.00.
Is Diaceutics' Growth Rank too high?
Diaceutics' current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Growth Rank compare to VEEV and BTSG?
Diaceutics' Growth Rank of 10 can be compared against companies in the Healthcare Providers & Services industry. Historically, Diaceutics' own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Healthcare Providers & Services company?
A good Growth Rank depends on the Healthcare Providers & Services industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Diaceutics and its competitors. Diaceutics's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Growth Rank is 10 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (DIUXF) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05. GuruFocus considers Diaceutics to be Fairly Valued.

Key valuation signals for DIUXF:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DXRX:UK7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score

Get the complete analysis for DIUXF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$2.05
GF Value